Sean Conrad is a patent agent in the firm’s Pittsburgh office. He is a member of the IP Procurement and Portfolio Management practice group.
He focuses his practice in the areas of patent preparation, patent prosecution, and client counseling with an emphasis in biotechnology. Sean has prepared and prosecuted patent applications for a range of biotechnologies including: gene therapy, gene editing, CRISPR gene editing, recombinant adeno-associated viruses (AAVs), large molecule therapeutics, immunotherapy, stem cell therapy, biological products, and bioassays. Since 2016, Sean has drafted numerous patent applications and conducted freedom-to-operate studies that focus on CRISPR gene editing, one of the hottest areas in biotechnology.